Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) Return on Capital Employed (2020 - 2026)

Nurix Therapeutics (NRIX) has disclosed Return on Capital Employed for 7 consecutive years, with 0.55% as the latest value for Q1 2026.

  • Quarterly Return on Capital Employed fell 14.0% to 0.55% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.55% through Feb 2026, down 14.0% year-over-year, with the annual reading at 0.48% for FY2025, 3.0% up from the prior year.
  • Return on Capital Employed for Q1 2026 was 0.55% at Nurix Therapeutics, roughly flat from 0.55% in the prior quarter.
  • The five-year high for Return on Capital Employed was 0.35% in Q1 2022, with the low at 0.64% in Q1 2024.
  • Average Return on Capital Employed over 5 years is 0.51%, with a median of 0.54% recorded in 2024.
  • The sharpest move saw Return on Capital Employed dropped -26bps in 2022, then rose 22bps in 2025.
  • Over 5 years, Return on Capital Employed stood at 0.5% in 2022, then decreased by -26bps to 0.63% in 2023, then surged by 32bps to 0.43% in 2024, then decreased by -28bps to 0.55% in 2025, then fell by 0bps to 0.55% in 2026.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.55%, 0.55%, and 0.56% for Q1 2026, Q4 2025, and Q3 2025 respectively.